VRTX

Ticker

VRTX

Congressional Trades

by 7 members

Ticker Intelligence Brief

Who in Congress traded VRTX, when, and what happened after?

A ticker-first view for retail/data users: latest disclosure, largest range, disclosure lag, party flow, contracts, lobbying, and source-linked receipts.

Latest receipt

David Taylor

SELL · 2026-01-29

Largest range

$15K – $50K

Jefferson Shreve

Slowest filing

326d

Tommy Tuberville

Best vs SPY

4.0%

David Taylor

Buys

37%

Sells

63%

Total Volume

$250K

midpoint

Unique Traders

members

Party Breakdown

Democrats1 · 5%

Republicans18 · 95%

Party Trading Divergence

Democrat vs. Republican buy / sell pressure by monthMODERATE

Bar length = total trades. Color = net sentiment — green = net buying, red = net selling. Months with no activity hidden.

Democrat ←

Month

→ Republican

—

Oct '22

1▲

—

May '24

0▲2▼

—

Oct '24

1▲

—

Dec '24

1▲

—

Feb '25

1▲

—

Mar '25

1▲1▼

—

May '25

0▲2▼

—

Jun '25

0▲4▼

—

Aug '25

2▲

—

Jan '26

0▲2▼

Democrats0▲0▼Neutral

Republicans7▲11▼Net sellers

Net buyingNet selling⚡ Party split

💼 Lobbying Filings

all →

2026-04-20$80K
VERTEX PHARMACEUTICALS INCORPORATED
Federal budget issues Alternatives to PAIN Act, IRA, innovation, health disparities, orphan drugs, drug pricing in federal programs, opioid alternative medicines, awareness of rare kidney disorders Medicare & Medicaid payment and coverage issues
2026-04-20$80K
VERTEX PHARMACEUTICALS INCORPORATED
Access to innovative non-opioid medicines. Access to innovative non-opioid medicines; Alternatives to PAIN, H.R. 1227; Alternatives to PAIN, S. 475.
2026-04-20$60K
VERTEX PHARMACEUTICALS INCORPORATED
Monitor issues related to 340b; Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders and expiring Advanced Premium Tax Credits (APTC) H.R. 1227/S. 475, Alternatives to PAIN Act and issues related to payment policies for non-opioid pain medication; Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to Senate Finance Dear Colleague process
2026-04-20$50K
VERTEX PHARMACEUTICALS INCORPORATED
Patient access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; Awareness of Cystic Fibrosis and Sickle Cell Disease; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; HR 1227 and S. 375
2026-04-20$30K
VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about precision medicine. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about non-opioid pain therapies.H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act. General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Education about the importance of access to non-opioid pain therapies for Medicare beneficiaries. H.R.1227/S.475 Alternatives to Prevent Addiction in the Nation (Alternatives to PAIN) Act.
2026-04-20$20K
VERTEX PHARMACEUTICALS INCORPORATED
FY2027 Appropriations bills. FY2027 Appropriations bills.
2026-04-20$0
VERTEX PHARMACEUTICALS INCORPORATED
2026-04-19$60K
TIBER CREEK GROUP (ON BEHALF OF VERTEX PHARMACEUTICALS)
2026-04-19$60K
VERTEX PHARMACEUTICALS
Issues related to drug pricing; Issues related to H.R. 1227/S. 475 - Alternatives to PAIN Act; Issues related to H.R. 1518 - New Era of Preventing End-Stage Kidney Disease Act. Issues related to coverage of opioid alternatives.
2026-04-18$50K
VERTEX PHARMACEUTICALS INCORPORATED
HR 1227, Alternatives to PAIN Act.

Congressional Momentum

buy vs. sell pressureDISTRIBUTING

Score 0–100: above 50 = net buying pressure, below 50 = net selling. Signal based on last 90 days.

Last 30 Days

No trades

Last 90 Days

No trades

All-Time

▼42

7 buys19 total12 sells

$105K buys · $145K sells

Cumulative Net Position (buy vol − sell vol)

-$40K

2019-0219 trades plotted2026-01

Best Timers

avg excess return vs SPY · VRTX trades only6 members w/ alpha data

Excess return = stock price change minus SPY change over the same holding window.Congress avg: -26.0%· 0% of traders beat SPY on this name

Top Alpha Generators

R:6House:5Senate:1

underperformed SPY|beat SPY

1st

David Taylor

-3.2%

2×

2nd

Lisa McClain

-22.1%

3×

3rd

Julia Letlow

-30.0%

1×

4th

Tommy Tuberville

-30.0%

1×

5th

Jefferson Shreve

-30.8%

3×

6th

Byron Donalds

-39.9%

1×

Worst Timers

bottom 5 by avg excess return

underperformed SPY|beat SPY

Byron Donalds

-39.9%

1×

Jefferson Shreve

-30.8%

3×

Tommy Tuberville

-30.0%

1×

Julia Letlow

-30.0%

1×

Lisa McClain

-22.1%

3×

Worst single trade: Jefferson Shreve (-41.9%)Best single trade: David Taylor (+4.0%)

Timing Fingerprint

filing delay vs. excess return over SPY · 11 tradesCongress avg -24.1% vs SPY

Each dot = one disclosed trade. X-axis = days between trade and STOCK Act filing.Y-axis = return above (or below) SPY over the subsequent holding window. Upper-right = late filers who beat the market.

9% of trades beat SPYavg excess -24.1%avg delay 91d5 buys6 sellsBuySellOther· dot size ∝ trade size

Trade Activity Timeline

Congressional buys & sells by month · last 11 months w/ activity

19/02

22/10

24/05

24/10

24/12

25/02

25/03

25/05

25/06

25/08

26/01

BuysSellsOtherHigh-volume month

Who Moved First

each row = one member · sorted by earliest disclosed trade

5 buyers ·6 sellers

BuySellOtherDot size ∝ trade size · top 7 most-active traders shown

Seasonal Rhythm

Congress buy/sell pressure by month & year

Each cell = one calendar month. Green = net Congress buying, red = net selling. Intensity ∝ consensus strength. Hover for details.

Net buyingNet sellingNo trades · number = trade count

Peak buy month: Aug · Peak sell month: May

Congressional Conviction Timeline

net positioning · alpha track recordBEARISH

7 buys12 sellscumulative α -119.7%11mo tracked

Monthly Net Flow (Buys − Sells)

Cumulative Excess Return on Congressional Buys vs SPY

All Disclosed Trades

Date	Member	Action	Amount	Filing Delay	Receipt
2026-01-29	RDavid Taylor	SELL	$1K – $15K	5d	receipt →
2026-01-29	RDavid Taylor	SELL	$1K – $15K	4d	receipt →
2024-10-23	RJulia Letlow	BUY	$1K – $15K	447d	receipt →
2025-08-07	RDavid Taylor	BUY	$1K – $15K	27d	receipt →
2025-08-07	RDavid Taylor	BUY	$1K – $15K	26d	receipt →
2025-06-11	RLisa McClain	SELL	$1K – $15K	64d	receipt →
2025-06-10	RLisa McClain	SELL	$1K – $15K	65d	receipt →
2025-06-11	RLisa McClain	SELL	$1K – $15K	63d	receipt →
2025-06-10	RLisa McClain	SELL	$1K – $15K	64d	receipt →
2024-12-11	RLisa McClain	BUY	$1K – $15K	245d	receipt →
2025-05-12	RJefferson Shreve	SELL	$15K – $50K	42d	receipt →
2025-05-12	RJefferson Shreve	SELL	$15K – $50K	41d	receipt →
2025-03-20	RByron Donalds	SELL	$1K – $15K	25d	receipt →
2025-03-13	RJefferson Shreve	BUY	$15K – $50K	29d	receipt →
2025-02-24	RJefferson Shreve	BUY	$15K – $50K	13d	receipt →
2024-05-03	RTommy Tuberville	SELL	$1K – $15K	42d	receipt →
2024-05-03	RTommy Tuberville	SELL	$1K – $15K	42d	receipt →
2022-10-06	RTommy Tuberville	BUY	$1K – $15K	326d	receipt →
2019-02-04	DJohn Reed	SELL	$1K – $15K	1666d	receipt →